Welcome to our dedicated page for Day One Biopharmaceuticals SEC filings (Ticker: DAWN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on clinical data releases, financial results, and material corporate agreements for this commercial-stage biopharmaceutical company focused on targeted cancer therapies.
Day One uses Form 8-K to report material events such as updated three-year data from the pivotal FIREFLY-1 trial of OJEMDA™ (tovorafenib) in pediatric low-grade glioma, financial results for specific quarters, and changes to corporate presentations. For example, an 8-K dated November 24, 2025 describes FIREFLY-1 efficacy and safety outcomes, while other 8-Ks attach press releases and slide decks summarizing OJEMDA net product revenue, license revenue, operating expenses, and cash balances.
Filings also document transactional and corporate actions. An 8-K filed in November 2025 outlines the Agreement and Plan of Merger through which Day One agreed to acquire Mersana Therapeutics via a tender offer and subsequent merger, including the structure of cash consideration and contingent value rights. Another 8-K describes an option repricing approved by the board of directors, providing detail on how stock options for certain directors and employees are adjusted and conditioned on continued service.
Through these SEC documents, readers can examine how Day One reports clinical trial outcomes, such as response rates and treatment-free intervals from FIREFLY-1, as well as how it communicates financial performance and corporate governance decisions. Stock Titan’s interface surfaces these filings alongside AI-powered summaries that highlight key points, helping users quickly understand the context of each report while preserving access to the full underlying documents.
In addition to 8-Ks, investors may use this page as a starting point to locate Day One’s annual and quarterly reports, which provide broader overviews of its oncology pipeline, including OJEMDA, DAY301, and Emi-Le, and its status as a Nasdaq Global Select Market registrant under the symbol DAWN.
Day One Biopharmaceuticals Inc. Schedule 13G/A reports that FMR LLC (with Abigail P. Johnson listed) beneficially owns 23,639.69 shares of common stock, representing 0.0% of the class as reported. The filing is an amendment and is signed under powers of attorney dated in 2023.
Day One Biopharmaceuticals Inc received an amended Schedule 13G/A from The Vanguard Group reporting beneficial ownership of 0 shares of Common Stock, representing 0% of the class as disclosed in the amendment. The filing explains an internal realignment completed on January 12, 2026 that led certain Vanguard subsidiaries and business divisions to report holdings separately, and the form is signed by Ashley Grim, Head of Global Fund Administration.
Servier Parties amend Schedule TO for Day One Biopharmaceuticals. Servier S.A.S., Servier Pharmaceuticals LLC and Purchaser Servier Detroit Inc. filed Amendment No. 1 to their Schedule TO, supplementing the pending tender offer for all issued and outstanding common shares of Day One Biopharmaceuticals by adding an Integration Presentation as an exhibit.
Day One Biopharmaceuticals recommends that stockholders accept a cash tender offer by Servier at $21.50 per share. The Offer, commenced March 26, 2026 and scheduled to expire April 22, 2026, is subject to conditions including at least a majority of Shares tendered, HSR clearance and other customary closing conditions. Day One had 103,317,336 Shares outstanding as of March 20, 2026; pre-funded warrants to purchase 827,586 shares are outstanding. Following the Offer and subject to conditions, Purchaser will merge into Day One under Section 251(h) of the DGCL and Day One will become a wholly owned subsidiary of Parent. Company executives and directors beneficially owned 2,418,391 Shares as of March 20, 2026 and, if tendered and accepted, would receive approximately $51,995,407 in the aggregate before withholding.
Day One Biopharmaceuticals, Inc. announced a cash tender offer by Servier Detroit Inc. to acquire all issued and outstanding common shares at $21.50 per share. The offer is made pursuant to the Offer to Purchase dated March 26, 2026 and is payable in cash, net to stockholders, without interest and less any applicable tax withholding. The Schedule TO incorporates the Offer to Purchase and related Letter of Transmittal and lists the Agreement and Plan of Merger dated March 6, 2026 as an exhibit. The filing includes customary transaction exhibits and communications related to the tender offer.
Day One Biopharmaceuticals is the subject of a planned tender offer by Servier and its subsidiaries pursuant to an Agreement and Plan of Merger dated March 6, 2026. This Schedule TO excerpt discloses preliminary communications only; the tender offer has not commenced and will be made by separate offer documents filed on Schedule TO.
The communication urges holders to read the forthcoming offer to purchase, related letter of transmittal and the Company’s solicitation/recommendation on Schedule 14D-9 when filed. It also lists customary forward-looking statement risks and provides an exhibit reference to a BIO Europe presentation.
Day One Biopharmaceuticals reported beneficial ownership of 5.44% of its common stock, equal to 5,615,390 shares, as disclosed on 03/12/2026. The position is held by funds managed by Glazer Capital, LLC and is reported jointly by Glazer Capital and Paul J. Glazer. The filing states that Glazer Capital Enhanced Master Fund, Ltd., a Glazer Fund, has the right to receive proceeds from the sale of more than 5% of the outstanding common stock.
Day One Biopharmaceuticals, Inc. filed an amended current report to add full financial details for its acquisition of Mersana Therapeutics, Inc. completed on January 6, 2026. The deal totals an estimated fair value of $173.0 million, including $125.0 million in cash and $48.0 million of contingent value rights (CVRs).
Each Mersana share received $25.00 in cash plus one non‑tradable CVR that may pay up to an additional $30.25 in cash upon achieving specified regulatory, commercial and net sales milestones. The aggregate undiscounted maximum contingent consideration is about $156.0 million.
Preliminary purchase accounting assigns $196.9 million to identifiable intangible assets and $36.7 million to goodwill. Unaudited pro forma results show combined revenue of $171.7 million and a net loss of $180.5 million for 2024, and revenue of $121.3 million with a net loss of $145.9 million for the nine months ended September 30, 2025.
Day One Biopharmaceuticals, Inc. is the subject of a planned tender offer by Servier and its subsidiaries pursuant to the Agreement and Plan of Merger, dated as of March 6, 2026, for all issued and outstanding shares of Day One common stock.
The communication states the tender offer has not yet commenced and that formal tender offer materials and a solicitation/recommendation statement will be filed with the SEC when the offer is launched; completion is conditioned on customary terms and regulatory and other closing conditions.
Day One Biopharmaceuticals, Inc. is the subject of a planned tender offer by Servier S.A.S. and its subsidiaries pursuant to an Agreement and Plan of Merger dated March 6, 2026. The announcement describes preliminary communications before the tender offer commences and states that formal Schedule TO materials will be filed when the offer begins.